Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) FCF Margin (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of FCF Margin data on record, last reported at 53905.79% in Q4 2025.

  • For Q4 2025, FCF Margin fell 5107753.0% year-over-year to 53905.79%; the TTM value through Dec 2025 reached 13829.06%, down 1155418.0%, while the annual FY2025 figure was 13829.06%, 1155418.0% down from the prior year.
  • FCF Margin reached 53905.79% in Q4 2025 per CLDX's latest filing, down from 4904000.0% in the prior quarter.
  • Across five years, FCF Margin topped out at 4904000.0% in Q3 2025 and bottomed at 53905.79% in Q4 2025.
  • Average FCF Margin over 5 years is 236584.17%, with a median of 3734.54% recorded in 2021.
  • The widest YoY moves for FCF Margin: up 490575124bps in 2025, down -5107753bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 4454.19% in 2021, then soared by 69bps to 1363.73% in 2022, then skyrocketed by 41bps to 803.66% in 2023, then crashed by -252bps to 2828.26% in 2024, then tumbled by -1806bps to 53905.79% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 53905.79% in Q4 2025, 4904000.0% in Q3 2025, and 6130.96% in Q2 2025.